1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow CPI-0610: new trials by email Literature Review of CPI-0610 trials Research Report on CPI-0610
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors CPI-0610 - Peripheral Nerve Tumors | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2017-05-05 | 2018-09-11 | |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies Pelabresib, Ruxolitinib - Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 336 | 2014-07-16 | 2026-06-04 |
Bone Marrow Diseases (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neurofibrosarcoma (1) · Peripheral Nervous System Neoplasms (1) · Precancerous Conditions (1) · Preleukemia (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1)
Constellation Pharmaceuticals (1) · University of Texas Southwestern Medical Center (1)
United States (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
PMID 36881782, PMID 37530627, PMID 38259250
2018 (1)